Moreover, activated HRAS mutations were detected in nonalcoholic fatty liver disease (NAFLD)–associated HCC in mice (Shen et al., 2016), which is increasingly regarded as a promotor of hepatocarcinogenesis. The gene discussed is HRAS; the disease is hepatocellular carcinoma.